



October 1, 2015

TransEnterix, Inc. Appoints Global Executive, Anthony Fernando to Lead SOFAR Integration

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that Anthony Fernando, an executive with significant global experience, has been appointed to lead the integration of SOFAR's robotic surgery division and named Managing Director of TransEnterix Italia. Mr. Fernando joined TransEnterix in August 2015 as Vice President International Development and was an integral part of the evaluation and structuring of the SOFAR robotics division acquisition. Mr. Fernando will report directly to TransEnterix's CEO Todd M. Pope.

"We are pleased to announce Anthony's expanded role as the leader of the SOFAR robotics integration. He has a tremendous amount of experience leading innovation and managing business operations," said Todd M. Pope, Chief Executive Officer of TransEnterix. "As we execute on our strategy to become a global surgical robotics company, it was important to expand our team with someone who has both an in-depth knowledge of the medical technology space as well as broad experience in international markets."

Mr. Fernando joins TransEnterix with over 15 years of experience driving business growth through innovation for healthcare companies, with over half of that time spent managing teams globally. Most recently, he served as Vice President of Innovation and Technology within the international group at Stryker Corporation (NYSE:SYK), where he was responsible for innovation and research and development across Stryker's medical device portfolio. Prior to joining Stryker, Mr. Fernando held positions at Becton Dickinson & Company (NYSE:BDX), PerkinElmer Inc. (NASDAQ:PKI) and Varian, Inc. where he served as the Director Operations/General Manager of the Pharmaceutical Products business unit. Mr. Fernando holds both a Master's of Science in Mechanical Engineering, with an emphasis on Robotics and Automation, and a Master's of Business Administration.

"Having spent the last 15+ years working for multi-national technology companies, in the USA and Internationally, I have seen first-hand the tremendous opportunity that exists for innovative products and business models that address unmet needs to drive significant growth," said Fernando. "I am excited to join TransEnterix as we execute on our global robotics growth strategy."

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the development and commercialization of the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform, and the commercialization of ALF-X®, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye tracking camera control. The SurgiBot System is not yet available for sale in any market. The ALF-X has been granted a CE Mark but is not available for sale in the US. For more information, visit the TransEnterix website at www.transenterix.com.

Forward Looking Statements

This press release includes statements relating to TransEnterix's integration of the SOFAR robotics division acquisition and its integration. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. For a discussion of the most significant risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q filed on August 6, 2015 and other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on [businesswire.com](http://www.businesswire.com/news/home/20151001006653/en/): <http://www.businesswire.com/news/home/20151001006653/en/>

Westwicke Partners

Investor Contact:

Mark Klausner, 443-213-0501

transenterix@westwicke.com

or

TransEnterix, Inc.

Media Contact:

Mohan Nathan, 919-917-6559

mnathan@transenterix.com

Source: TransEnterix, Inc.

News Provided by Acquire Media